Introduction
============

Based on GLOBOCAN estimates, approximately 14.1 million new cancer cases and 8.2 million deaths occurred in 2012 worldwide [@B1]. Although diagnosis and therapy for cancer has made great progress, the prognosis of most cancers was still poor on account of recurrence, metastasis and chemoradio-resistance [@B2], [@B3]. Clinical characteristics, such as stage, grade and histologic type, etc. are the most crucial prognostic factors to predict clinical outcomes [@B4]. However, individuals with the same classical parameters often end up with various outcomes [@B5]. In recent years, molecular classification beyond to stage and grade is just unfolding for providing accurate prediction of clinical outcome based on the expression of cancer-related biomarkers, by which treatment could be adjusted according to molecular status[@B6].

The MCMs are ubiquitously expressed proteins, including MCM1-10. Among these proteins, MCM2-7 form a hexamer called the MCM complex which are all AAA+ ATPases and share partial homologous sequences[@B7]. MCM complex plays an important role in the initiation of DNA replication. In G1-phase, MCM2-7 replicative helicase binds around double-stranded DNA (dsDNA) in the form of inactive head-to-head dimer. In S-phase, the active MCM2-7 double hexamer (MCM DH) conducts bidirectional DNA synthesis at eukaryotic origins[@B8]. In addition, the MCM complex contributes to replication elongation, cohesion, condensation, transcription and recombination of DNA molecule[@B9]. Each member of MCM complex may plays a distinct or similar role in the regulation of cell behavior. Previous evidence showed that MCM complex subunits have been implicated in cell proliferation, invasion and metastasis [@B10]-[@B12].

Controversial results have been reported among a variety of cancers. A number of studies demonstrated that overexpression of MCMs were found to be significantly correlated to a poor outcome in cancers, such as gastric cancer(GC) [@B13], [@B14], non-benign epithelial ovarian tumor [@B15], breast cancer [@B16] , glioma [@B17], non-pure-(BAC)bronchioloalveolar carcinoma [@B18], gallbladder [@B19], osteosarcoma[@B20] and muscle-invasive urothelial cancer [@B21]. High MCMs expression was correlation with high TNM stage, lymph node metastasis and recurrence in above cancers, which suggested increased expression of MCM2 might be associated with increased malignancy of these cancers. However, other studies for ER-positive breast cancer [@B22], small lung adenocarcinomas [@B23] and colorectal cancer (CRC) [@B24] demonstrated the potential role of MCMs overexpression in predicting better prognosis. In ER-positive breast cancer study, Ali et al. pointed out that high MCM2 expression was correlated with human epidermal growth-factor receptor 2 (HER-2)-positive, and HER-2-positive was known as a good biomarker for prognosis of breast cancer [@B22]. In addition, some researches indicated that MCMs expression was not related with survival of non-small cell lung cancer (NSCLC)[@B25] and hepatocellular carcinoma (HCC)[@B26]. The effects of MCMs expression in prognosis of cancers have been investigated but the results have not yet reached a consensus. Up to now, no meta-analysis has investigated the prognosis of various cancers in relation to MCMs expression. To explore whether expression of MCMs was correlated with prognosis of overall cancer and specific cancer subtypes, we performed this meta-analysis.

In our study, 31 studies with 7653 patients were included. Our results indicated that positive or high expression of MCM2, MCM5 and MCM7 may predict worse prognosis of cancers. Our results may be helpful to provide clinical evidence for effective treatment of cancer patients.

Materials and Methods
=====================

Search Strategy
---------------

Literature search was performed in the electronic platforms of PubMed, Web of Science, Cochrane Library and Embase. The last search date was October 10, 2017. The search strategy was used as: \'MCM2/CDCL1/BM28\', \'MCM3/P102/RLF\', \'MCM4/CDC21\', \'MCM5/P1Cdc46\', \'MCM6/Mis5\', \'MCM7/CDC47\' and \'cancer/carcinoma/neoplasm/neoplasia/tumor/tumour\'. Article language was limited to English and Chinese. The references of all relevant articles were manually reviewed to find potentially relevant articles. To evaluate the quality of studies, we used the Newcastle-Ottawa Scale (NOS). We assigned the studies of high quality a scored ≥ 6 stars. The results are shown in Table [1](#T1){ref-type="table"}. Two investigators assessed the eligibility of the studies independently and reached agreement by discussion.

Inclusion and Exclusion Criteria
--------------------------------

Inclusion criteria: (1) studies concerning the survival outcomes of cancer patients with high/positive MCMs expression versus low/negative MCMs expression; (2) studies with complete information for assessment of hazard ratios (HRs) or risk ratios (RRs) and their 95% confidence intervals (CIs) for overall survival (OS); (3) original articles in English. Exclusion criteria: (1) study without sufficient data; (2) letters, editorials, case reports, reviews, comments or meeting abstracts.

Data Extraction
---------------

Two authors (Kaihua Gou and Xue Feng) extracted the data of included studies. The following extracted information was recorded: first author\'s name, year of publication, number of patient, ethnicity, tumor stage, detection method, cut-off value, analytical method, HRs or RRs with their 95 % CIs for OS and study quality. If the above-mentioned data was not available, items were regarded as \'not reported\'.

Statistical Analyses
--------------------

STATA (Version 11.0; StataCorp, College Station, TX) was used to conduct statistical analysis. Pooled HRs or RRs and their 95% CIs were calculated to measure the impact of MCMs expression on the survival of patients. I^2^ test and Q test were performed to assess heterogeneity among the studies (P\<0.10 indicates significant heterogeneity between studies). A fixed-effect model was used to calculate the pooled HRs or RRs when heterogeneity between studies was not significant. Otherwise, a random-effect model was applied. Sensitivity analysis was carried out to explore heterogeneity when significant heterogeneity was manifested. Subgroup analyses were conducted to explore the effects of source of controls and cancer types. In addition, Egger\'s test and Begg\'s test were performed to assess publication bias among included studies. P value\<0.05 was considered as statistically significant. We followed the PRISMA statement (S1) to design and report our meta-analysis.

Results
=======

Study Characteristics
---------------------

In total, 2813 potentially non-duplicated studies were obtained after the initial database searches. After excluding 2546 articles based on title/abstract review, 267 articles were retrieved. Then, another 217 studies were excluded after review of the full texts, including 97 articles of insufficient data, 61 articles of meeting abstract, 23 reviews, 2 article without full text, 1 non-English article and 2 articles quality ≤ 5stars. Finally, 31eligible studies which fulfilled all inclusion criteria were selected in this meta-analysis [@B13]-[@B24], [@B26]-[@B44]. The study selection procedure is outlined in Figure [1](#F1){ref-type="fig"}. The principal characteristics of the included studies are summarized in Table [1](#T1){ref-type="table"}. The overall sample-size added up to 7653 participants. Of the 31 studies, the populations of 17 studies were Asian [@B13], [@B14], [@B17]-[@B20], [@B23], [@B24], [@B28]-[@B30], [@B32], [@B34], [@B37]-[@B40], [@B44], and the remaining 13 studies were Caucasian [@B15], [@B16], [@B21], [@B22], [@B26], [@B27], [@B31], [@B33], [@B35], [@B36], [@B41], [@B42]. Nine studies investigated the association of MCM2 expression with OS for HR [@B14]-[@B16], [@B20], [@B22], [@B24], [@B31], [@B35], [@B41], [@B42] and 8 for RR [@B13], [@B17]-[@B19], [@B21], [@B23], [@B29], [@B36] separately; 3 articles investigated the association of MCM5 with OS for HR [@B15], [@B27], [@B37]; 6 studies in association with MCM7 were included respectively for HR [@B26], [@B30], [@B38]-[@B40], [@B43] and 7 for RR[@B17], [@B23], [@B28], [@B33], [@B41], [@B44], [@B45]. The types of cancers included HCC, OSCC, NSCLC and so on. Data concerning different cancers and ethnicity were considered as separate studies in the subgroup analysis.

Association of MCMs with OS
---------------------------

The pooled HR was presented in Table [2](#T2){ref-type="table"}. Carriers with increased MCM2 expression were not associated with worse OS compared with decreased expression (HR=1.11, 95% CI=0.98-1.26, P=0.094, Figure [2](#F2){ref-type="fig"}). However, individuals with high expression of MCM5 and MCM7 were correlated with worse OS compared with low expression (HR=1.04, 95% CI=1.01-1.08, P=0.020; HR=1.78, 95% CI=1.04-3.02, P=0.035, respectively, Figures [4](#F4){ref-type="fig"} and [5](#F5){ref-type="fig"}). As for ethnicity, patients with increased expression of MCM7 were significantly associated with shorter OS in Asian (HR=2.49, 95%CI=1.93-3.21, P\<0.001). In regard to cancer types, the pooled HR of MCM7 high/positive expression was 2.51 in lung cancer (Table [2](#T2){ref-type="table"}).

The pooled RR of included studies are presented in Table [3](#T3){ref-type="table"}. Patients with increased expression of MCM2 and MCM7 were significantly associated with shorter OS (RR=2.30, 95% CI=1.14-4.63, P=0.019; RR=3.52, 95% CI=2.01-6.18, P\<0.001, respectively, Figures [3](#F3){ref-type="fig"} and [6](#F6){ref-type="fig"}). In the subgroup analysis of cancer type, increased expression of MCM2 was related to poor OS of digestive system cancer (RR=2.36, 95% CI=1.57-3.55, P\<0.001) but no significant association was found for lung cancer (RR=1.01, 95% CI=0.42-2.41, P=0.992). In the comparison of OS between low/negative and high/positive MCM7 expression, low/negative was significantly associated with a better OS in Asian and Caucasian (HR=3.81, 95%CI=1.84-7.87, P\<0.001; HR=2.51, 95%CI=1.57-4.00, P\<0.001, respectively). In lung cancer, increased expression of MCM7 were significantly associated with shorter OS (HR=7.84, 95%CI=2.14-28.74, P=0.002).

Heterogeneity Test, Sensitivity Analysis, and Publication Bias
--------------------------------------------------------------

For MCMs, significant heterogeneity was observed except for MCM5, which could not be completely explained by design or subgroup analysis. Because the numbers of included studies for MCM5 was \<5, we did not perform sensitivity analyses. The results of the sensitivity analysis for MCM2 and MCM7 showed that the exclusion of each single study did not change the statistical significance except MCM7 for HR.

We performed the Begg\'s and Egger\'s tests to identify potential publication bias. The detailed results for publication bias test were summarized in Table [4](#T4){ref-type="table"}. No significant publication bias was found in this meta-analysis.

Discussion
==========

Since the prognosis significance of MCM family proteins in cancers is controversial, a quantitative meta-analysis is employed in our study. As far as we are concerned, this is the first meta-analysis to evaluate the correlation between expression levels of MCMs and survival of cancer. By analyzing the data extracted from 31 full-text publications, we revealed that high expression of MCM2, MCM5 and MCM7 might be associated with poor OS.

The pooled RR results showed that high MCM2 expression was associated with patients\' poor OS. A number of researches have indicated the role of MCM2 in cancer development. Liu et al. reported that positive MCM2 expression was significantly correlation with high TNM stage, large tumor size, lymph node metastasis and invasion in squamous cell (SC)/adenosquamous carcinoma (ASC) and adenocarcinoma (AC) of the gallbladder [@B19]. Similarly, Giaginis et al. found that MCM2 expression was significantly correlation with the tumors grade, vascular invasion and Dukes\' stage in CRC [@B46]. In addition, MCM2 expression was found to be independent predictors of recurrence in bladder cancer [@B47]. Mutation of TP53 is associated with a poorer prognosis and this abnormality is common in tumors with high expression of MCM2 and MCM7 [@B48]. These findings suggested that high MCM2 expression in cancers tends to indicate higher biological malignant aggressiveness, which are consistent with our results.

The present study pointed out that the OS of patients with high expression of MCM5 was significantly shorter than that of patients with low expression. For MCM5, significant correlation was found between the higher MCM5 expression and OSCCs with larger tumor size, higher clinical stage, higher histological grade, lymph node metastasis and deeper invasion depth [@B37]. Additionally, the expression levels of MCM5 were also found to be increased in advancing tumor stage of epithelial ovarian adenocarcinoma [@B15] and muscle-invasive urothelial cancer [@B21]. Similarly, it has been reported that MCM5 silencing reduced cell proliferation in human anaplastic thyroid cancer-derived cell lines [@B49]. In human melanocyte cell line, Sox10 inhibited proliferation by down-regulating the expression of MCM5. [@B50]. Estrogen receptor beta increased cell proliferation and invasion by up-regulating expression of MCM5 in bladder cancer cell lines [@B51]. Therefore, overexpression of MCM5 might be linked with increased proliferative rate of cancer cells. These results, at least in part, explained the neoplasms with higher level expression of MCM5 own more aggressive biological behaviors. Effective therapeutic target is very essential for the clinical treatment of cancers. Our results would provide useful information about the potential of MCM5 as a therapeutic target.

In the present study, we have found that high MCM7 expression was correlated with poor OS both in HR and RR. We suggest possibly following explanations of why MCM7 expression affected OS. The levels of MCM7 protein expression was higher in Grade II than in Grade I in meningioma [@B52]. Guan et al. found MCM7 expression was elevated with increased tumor grade in papillary urothelial neoplasia [@B53]. Feng et al. revealed that MCM7 were associated with the lymph nodes metastasis and the clinical stage in OSCC [@B54]. However, Ishibashi et al. conducted a study on the correlation between MCM7 expression and clinicopathological characteristics of CRC which was no statistical significance [@B55]. In vitro, low MCM7 expression significantly inhibited cell proliferation, colony formation and migration in esophageal carcinoma cell lines [@B56]. Similarly, Qu et al. indicated that MCM7 downregulation reduced proliferation by suppressing the expression of extracellular regulated kinase 2 (ERK2), ERK3, ERK4 and ERK7 which were proteins of MAPK signaling pathway in HepG2 cell line [@B57]. Cell proliferation, worse clinical tumor stage, positive lymph nodes metastasis and recurrence were all unfavorable cancer parameters. The relations of MCM7 expression with these factors could support our finding of its potential as a prognostic biomarker. As for different populations, the current findings suggested that MCM7 expression might be a useful predictor for prognosis in Asian patients but not in Caucasian patients. The results of different ethnic background should be confirmed by future studies.

Kwok, H. F et al. suggested that MCM2-7 gene may be closely co-regulated by common transcription factors (AML-1a, GATA-1, SRY) in breast cancer [@B58]. Similar to above result, our study indicated that the pooled HR or RR of MCM2, MCM5 and MCM7 were all \>1, although MCM2 pooled HR do not reach statistical significance. Therefore, we point out that MCMs expression may be associated with the prognosis of cancers as a complex. However, contrary to our result, a conclusion that the presence of MCM2 protein disturbs the assembly of MCM4, MCM6, and MCM7 proteins to suppress the DNA helicase activity was draw from study on Hela cells [@B59]. In that case, high level expression of MCM2 would predict better prognosis. The discrepancy between above publication and our conclusion may be due to the condition that MCM2 protein modification lead to the function change of MCM4, 6 and 7 complex beside the amount of MCM2 protein.

Several limitations should be acknowledged in this meta-analysis. First, the sample size was not sufficiently large for MCM5. Second, all the studies included in the meta-analysis were published in English and Chinese, therefore publication bias might present in our study although the bias test did not show it. Third, the heterogeneity could not be totally eliminated by subgroup analysis and sensitivity analysis. The detecting methods of MCMs expression, cut-off value, source of antibodies, dilution ratios and surgical operation were different, which may cause heterogeneity between the included studies. Finally, the different survival analysis methods might affect the accuracy of outcome, although the most of the studies conducted multivariate analysis in Cox proportional hazards model.

Conclusions
===========

In summary, this meta-analysis found that high expression of MCM2, MCM5 and MCM7 were related with worse survival for cancer patients. However, before MCMs expression are routinely used in patient management, large-scale and well-designed studies on different ethnicities are still needed to validate the results of our meta-analysis.
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###### 

Characteristics of eligible studies in this meta-analysis.

  Author                  Year   Cancer type        Ethnicity   Number   Cutoff      TNM      U/M   Expression      Detection method   Study quality
  ----------------------- ------ ------------------ ----------- -------- ----------- -------- ----- --------------- ------------------ ---------------
  **MCM2**                                                                                                                             
  **Cheng, D. D.**        2017   Osteosarcoma       Chinese     129      2 scores    NR       M     Protein         IHC                6
  **Liu, Z.**             2016   GBC                Chinese     1060     25%         I-IV     M     Protein         IHC                7
  **Ali, H. R.**          2012   Breast cancer      British     1064     3 scores    NR       U/M   Protein         TMA & IHC          7
  **Yang, C.**            2012   Gastric cancer     Chinese     264      3 scores    I-IV     M     Protein         TMA & IHC          7
  **Zhao, D. B.**         2011   CRC                Chinese     306      51.20%      I-III    M     Protein         TMA & IHC          6
  **Wojnar, A.**          2011   Breast cancer      Polish      117      25%         I-IV     U     Protein         IHC                9
  **Fujioka, S.**         2009   Lung ACs           Japanese    100      14.60%      I        M     Protein         IHC                7
  **Loddo, M.**           2009   Breast cancer      British     182      30%         NR       U     Protein         IHC                7
  **Kayes, O. J.**        2009   Penile carcinoma   British     84       4%          I-IV     M     Protein         IHC                6
  **Tokuyasu, N.**        2008   Gastric cancer     Japanese    43       44%         NR       M     Protein         IHC                8
  **Gakiopoulou, H.**     2007   Ovarian AC         Greek       128      20%         I-IV     M     Protein         IHC                6
  **Yang, J.**            2006   NSCLC              American    128      25%         I-IIIA   U     Protein         IHC & WB           6
  **Korkolopoulou, P.**   2005   UC                 Greek       65       18%         II-IV    M     Protein         IHC                6
  **Gonzalez, M. A.**     2004   Breast cancer      British     164      50%         NR       U     Protein         TMA & IHC          7
  **Hashimoto, K.**       2004   Lung AC            Japanese    122      40%         I-III    U     Protein         IHC                7
  **Kato, H.**            2003   OSCC               Japanese    93       62.70%      I-IV     M     Protein         IHC                7
  **MCM5**                                                                                                                             
  **Yu, S. Y.**           2014   Oral SCC           Chinese     97       60%         I-IV     M     Protein         IHC                6
  **Giaginis, C.**        2011   Gastric cancer     Greek       66       NR          I-IV     M     Protein         IHC                7
  **Gakiopoulou, H.**     2007   Ovarian cancer     Greek       128      25%         I-IV     M     Protein         IHC                6
  **MCM7**                                                                                                                             
  **Almadori, G.**        2017   Laryngeal SCC      Italian     61       50%         I-IV     M     Protein         IHC                6
  **Karavias, D.**        2016   HCC                Greek       111      5 scores    I-IV     U     Protein         IHC                8
  **Deraco, M.**          2015   DMPM               Italian     170      NR          NR       U     Protein         IHC & TMA          6
  **Zhong, X.**           2015   OSCC               Chinese     139      50%         I-IV     M     Protein         IHC & TMA          7
  **Hua, C.**             2014   Glioma             Chinese     59       NR          II-IV    M     Protein & RNA   WB & qPCR          6
  **Zhong, X.**           2014   NSCLC              Chinese     270      50%         I-IV     M     Protein         IHC                8
  **Liu, Y. Z.**          2012   NSCLC              Chinese     494      50% & 10%   I-IV     M     Protein         IHC & ICC          6
  **Zhou, Y. M.**         2012   HCC                Chinese     87       30%         I-IV     M     Protein         IHC                7
  **Tolonen, T. T.**      2011   Prostate cancer    Finnish     292      20%         I-IV     U     Protein         IHC                6
  **Haruki, T.**          2011   Lung AC            Japanese    100      15.60%      NR       M     Protein         IHC                7
  **Hamamoto, Y.**        2010   STS                Japanese    109      17.40%      I-IV     M     Protein         IHC                6
  **Fujioka, S.**         2009   Lung AC            Japanese    100      20.20%      NR       M     Protein         IHC                7
  **Nishihara, K.**       2009   CRC                Japanese    191      58%         I-IV     U     Protein         IHC                7

IHC: immunohistochemistry; TMA: tissue microarray; qPCR: quantitative PCR; WB: western blot; HR: hazard ration; H: high expression; L: low expression; P: positive expression; N: negative expression; TNM: tumor-node-metastasis; M: multivariate analysis; U: univariate analysis; NR: not reported; NSCLC: non-small cell lung cancer; SCC: squamous cell cancer; AC: adenocarcinoma; GBC: gallbladder cancer; CRC: colorectal cancer; Laryngeal SCC: laryngeal squamous cell carcinoma; HCC: hepatocellular carcinoma; DMPM: Diffuse Malignant Peritoneal Mesothelioma; OSCC: oesophageal squamous cell carcinoma; STS: soft tissue sarcomas.

###### 

Meta-analysis results of the association between MCMs expression and overall survival for pooled HR.

  Categories   Group/subgroup            Data set number   HR(95%CI)             P value       Model   P~het~    I² (%)
  ------------ ------------------------- ----------------- --------------------- ------------- ------- --------- --------
  **MCM2**     Overall                   10                1.11(0.98-1.26)       0.0941        R       \<0.001   75.0%
               Digestive system cancer   2                 1.17(0.34-4.02)       0.809         R       \<0.001   94.1%
               Breast cancer             5                 1.20(0.97-1.48)       0.095         F       0.166     38.2%
               Asian                     3                 1.31(0.571-3.00)      0.525         R       \<0.001   91.4%
               Caucasian                 7                 1.09(1.00-1.19)       0.061         R       0.030     57.1%
  **MCM5**     Overall                   3                 **1.04(1.01-1.08)**   **0.020**     F       0.146     48.1%
  **MCM7**     Overall                   6                 **1.78(1.04-3.02)**   **0.035**     R       \<0.001   79.3%
               Digestive system cancer   3                 2.17(0.86-5.49)       0.101         R       0.017     75.5%
               Lung cancer               2                 **2.51(1.88-3.45)**   **\<0.001**   F       0.323     0.0%
               Asian                     5                 **2.49(1.93-3.21)**   **\<0.001**   F       0.169     40.5%

R: random effect model; F: fixed effect model.

###### 

Meta-analysis results of the association between MCMs expression and overall survival for pooled RR.

  Categories   Group/subgroup            Data set number   RR(95%CI)              P value       Model   P~het~    I² (%)
  ------------ ------------------------- ----------------- ---------------------- ------------- ------- --------- --------
  **MCM2**     Overall                   9                 **2.30(1.14-4.63)**    **0.019**     R       \<0.001   90.7%
               Lung cancer               3                 1.01(0.42-2.41)        0.992         R       0.013     77.1%
               Digestive system cancer   4                 **2.36(1.57-3.55)**    **\<0.001**   F       0.711     0.0%
               Asian                     7                 2.15(0.96-4.82)        0.064         R       \<0.001   90.5%
               Caucasian                 2                 2.90(0.58-14.40        0.193         R       0.004     87.8%
  **MCM7**     Overall                   7                 **3.50(2.01-6.18)**    **\<0.001**   R       0.002     70.7%
               Asian                     5                 **3.81(1.84-7.87)**    **\<0.001**   R       0.005     73.1%
               Caucasian                 2                 **2.51(1.57-4.00)**    **\<0.001**   F       0.403     0.0%
               Lung cancer               2                 **7.84(2.14-28.74)**   **0.02**      F       0.786     0.0%

###### 

Publication bias.

             z value   P value   t value   P value
  ---------- --------- --------- --------- ---------
  **HR**                                   
  **MCM2**   0.720     0.474     1.600     0.148
  **MCM5**   1.040     0.296     1.650     0.347
  **MCM7**   1.36      0.175     1.01      0.344
  **RR**                                   
  **MCM2**   0.730     0.466     -2.430    0.046
  **MCM7**   0.30      0.764     -0.34     0.751
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